Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Xu, Z., Pang, T. C. Y., Liu, A. C., Pothula, S. P., Mekapogu A. R., Perera C. J. et al. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Br. J. Cancer https://doi.org/10.1038/s41416-020-0782-1 (2020).

  2. 2.

    Le Large, T. Y. S., El Hassouni, B., Funel, N., Kok, B., Piersma, S. R., Pham, T. V. et al. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Ther. Adv. Med. Oncol. 11, 1758835919841233 (2019).

    Article  Google Scholar 

  3. 3.

    Firuzi, O., Che, P. P., El Hassouni, B., Buijs, M., Coppola, S., Lohr, M. et al. Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells. Cancers (Basel) 11, 638 (2019). https://doi.org/10.3390/cancers11050638.

    CAS  Article  Google Scholar 

  4. 4.

    Tomihara, H., Yamada, D., Eguchi, H., Iwagami, Y., Noda, T., Asaoka, T. et al. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Sci. 108, 398–407 (2017).

    CAS  Article  Google Scholar 

  5. 5.

    Rath, N. & Olson, M. F. Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nat. Med. 22, 462–463 (2016).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

P.P.C. was the principal investigator and takes primary responsibility for the article; A.G. provided essential input, G.J.P. and M.D. participated in the research design and edited the article; P.S. and E.G. supervised and edited the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Elisa Giovannetti.

Ethics declarations

Ethics approval and consent to participate

This study did not require ethical approval.

Data availability

All data generated or analysed during this study are included in this published article.

Competing interests

The authors declare no competing interests.

Funding information

This work was partially supported by the following grants: Zabawas Foundation—Cancer Center Amsterdam Foundation CCA2019-5-55 (P.S.), CCA2015-1-19 (E.G.), CCA2018-5-48 (E.G.), KWF Dutch Cancer Society—KWF project#11957 (E.G.), and Associazione Italiana per la Ricerca sul Cancro—AIRC/Start-Up grant (E.G.).

Additional information

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Che, P.P., Gregori, A., Peters, G.J. et al. Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-1003-7

Download citation